烟台正海生物科技股份有限公司 2025 年半年度报告摘要 证券代码：300653 证券简称：正海生物 公告编号：2025-028 一、重要提示 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 资者应当到证监 会指定媒体仔细阅读半年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 非标准审计意见提示 □适用 ?不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 □适用 ?不适用 公司计划不派发现金红利，不送红股，不以公积金转增股本。 烟台正海生物科技股份有限公司 烟台正海生物科技股份有限公司 2025 年半年度报告摘 要 二、公司基本情况 | 股票简称 | | 正海生物 | 股票代码 | 300653 | | --- | --- | --- | --- | --- | | 股票上市交易所 | | 深圳证券交易所 | | | | | 联系人和联系方式 | 董事会秘书 | | 证券事务代表 | | 姓名 | 赵丽 | | 吕杨琼 | | | 电话 | | 0535-6971993 | 0535-6971993 | | | 办公地址 | | 烟台经济技术开发 ...

Group 1 - The board of directors of Yantai Zhenghai Biological Technology Co., Ltd. held its eighth meeting of the fourth session on August 4, 2025, via telecommunication, with all 8 directors present [1] - The meeting approved the company's 2025 semi-annual report and its summary, confirming that the preparation process complies with relevant laws and regulations, and accurately reflects the company's actual situation [2][3] Group 2 - The board unanimously agreed to amend the company's articles of association and related rules, and to change the business scope, with details to be disclosed on the designated information disclosure website [3][5] - The board accepted the resignation of non-independent director Ni Ting and nominated Xu Yueli as a candidate for the non-independent director position [3][4] Group 3 - The board decided to dissolve the Strategic and Investment Committee, transferring its responsibilities to the board itself to enhance decision-making efficiency for major investments and financing [4] - The board approved several governance documents, including the establishment of a "Management System for Departing Directors and Senior Management" and modifications to various existing governance rules, all receiving unanimous support [5][6][7][8][9] Group 4 - The company plans to hold its first extraordinary shareholders' meeting of 2025 on August 27, 2025, to review the proposals discussed in the board meeting [9]

Group 1 - The fourth meeting of the supervisory board of Yantai Zhenghai Biological Technology Co., Ltd. was held on August 4, 2025, via communication, with all three supervisors present [1][2] - The supervisory board approved the procedures for the preparation and review of the company's 2025 semi-annual report, confirming that the report accurately reflects the company's actual situation without any false records or misleading statements [1][2] - The voting results showed unanimous support, with 100% of the attending supervisors voting in favor of the resolutions [2][3] Group 2 - The company plans to amend relevant provisions of its articles of association and change its business scope, which will be submitted for review at the first extraordinary shareholders' meeting of 2025 [2][3] - The company also intends to abolish the "Rules for Supervisory Board Meetings," with the details to be disclosed on the designated information disclosure website [2][3]

烟台正海生物科技股份有限公司 第一章 总则 第一条 为进一步加强烟台正海生物科技股份有限公司（以下简称"公司"）与投资者 和潜在投资者（以下统称"投资者"）之间的信息沟通，促进投资者对公司的了解和认同， 完善公司治理结构，规范公司投资者关系管理工作，根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）等法律、行 政法规、规范性文件的有关规定，结合公司实际情况，制定本制度。 第二条 投资者关系管理是指公司通过便利股东权利行使、信息披露、互动交流和诉求 处理等工作，加强与投资者和潜在投资者之间的沟通，增进投资者对公司的了解和认同，以 提升公司治理水平和企业整体价值，实现尊重投资者、回报投资者、保护投资者的相关活动。 第三条 公司投资者关系管理工作应严格遵守《公司法》、《证券法》等有关法律、法 规、规章及深圳证券交易所有关业务规则的规定。 第四条 公司进行投资者关系活动应当建立完备的投资者关系管理档案制度，投资者关 系管理档案至少应当包括下列内容： （一）投资者关系活动参与人员、时间、地点； 烟台正海生物科技股份有限公司 投资者关系管理制度 （二）投资者关系活 ...

Core Points - The document outlines the major transaction decision-making system of Yantai Zhenghai Biological Technology Co., Ltd, ensuring compliance with relevant laws and regulations [1] - The system aims to clarify the responsibilities and powers of the shareholders' meeting, board of directors, and general manager to enhance operational efficiency [1] Chapter 1: General Principles - The company must adhere to the Company Law and the Shenzhen Stock Exchange's rules while making transaction decisions [1] - Transactions include asset purchases or sales, external investments, financial assistance, guarantees, leasing, management contracts, donations, debt restructuring, licensing agreements, R&D project transfers, and rights waivers [1] Chapter 2: Transaction Approval Authority - Transactions exceeding certain thresholds must be submitted to the board of directors for review, including those where the total asset amount exceeds 10% of the latest audited total assets or where the transaction amount exceeds 50 million yuan [2][3] - Transactions that meet specific criteria, such as involving assets over 50% of total audited assets or generating profits over 50% of the latest audited net profit, must be submitted to the shareholders' meeting for approval [4] - For equity transactions that change the scope of consolidated financial statements, the entire asset and revenue of the corresponding company must be considered [4] - The company must hire qualified accounting firms to audit financial reports for equity transactions and qualified asset appraisal firms for non-cash asset transactions [5] - If the total asset amount or transaction amount reaches 30% of the latest audited total assets within 12 months, it must be disclosed and submitted for shareholder approval [6] - Financial assistance transactions require approval from two-thirds of the board and may need to be submitted to the shareholders' meeting under certain conditions [6] Chapter 3: Miscellaneous - The decision-making standards outlined in the document must be followed unless conflicting with national laws and regulations [7] - The company’s shareholders, directors, and independent directors have the right to supervise and question the general manager's actions [8] - The document will be implemented upon approval by the shareholders' meeting and is subject to interpretation by the board of directors [8]

Core Viewpoint - The financing and external guarantee management system of Yantai Zhenghai Biological Technology Co., Ltd. aims to protect investors' rights, regulate financing and guarantee behaviors, control asset operation risks, and ensure financial safety and stable development of the company [2][3]. Group 1: General Provisions - The system applies to the company and its wholly-owned and controlling subsidiaries [2]. - Financing refers to indirect financing from financial institutions, including various forms such as comprehensive credit, working capital loans, and bank guarantees [3]. - External guarantees involve providing guarantees, asset pledges, and other forms of security for other entities or individuals [3]. Group 2: Basic Regulations for External Guarantees - External guarantees must comply with relevant laws and the company's articles of association, following principles of equality, voluntariness, fairness, integrity, and mutual benefit [3]. - External guarantees are subject to unified management, and branches cannot provide guarantees without approval [3]. - Any external guarantee requires approval from the shareholders' meeting or the board of directors [3]. Group 3: Financing Approval Process - The finance management department is responsible for managing financing applications and conducting preliminary reviews [4]. - Financing amounts are limited to 10% of the latest audited net asset value for certain approvals and 20% for others, with higher amounts requiring board and shareholder approval [4][5]. - If the asset-liability ratio exceeds 70%, financing must be approved by the shareholders' meeting [5]. Group 4: External Guarantee Application and Investigation - Before deciding on an external guarantee, the company must assess the credit status of the guaranteed party and analyze the associated risks [6]. - The applicant must submit a guarantee application detailing the debt situation, business or project, risk assessment, and necessary documentation [6][7]. - The finance management department conducts a thorough investigation of the applicant's financial status and creditworthiness [7]. Group 5: Review of External Guarantees - External guarantees undergo a review process involving the finance management department and the board of directors, which assesses the financial status and risks associated with the guaranteed party [9][10]. - Guarantees exceeding certain thresholds require shareholder approval, particularly if they exceed 10% of the latest audited net assets or involve high-risk entities [10][11]. Group 6: Guarantee Contracts - Written guarantee contracts must be established after board or shareholder approval, detailing the nature of the debt, obligations, and liabilities [13][14]. - The finance management department must review the legality and completeness of guarantee contracts, ensuring compliance with laws and regulations [14][15]. Group 7: Execution and Risk Management - The finance management department is responsible for monitoring the execution of financing and guarantee contracts, ensuring compliance with the stipulated purposes [16][17]. - Continuous assessment of the financial status and operational changes of the guaranteed party is required to manage risks effectively [17][18].

买卖公司股份行为规范 烟台正海生物科技股份有限公司 控股股东、实际控制人、董事、高级管理人员 买卖公司股份的行为规范 第一章 总则 第一条 为规范对烟台正海生物科技股份有限公司（以下简称"公司"或"本 公司"）控股股东、实际控制人、董事、高级管理人员买卖公司股份的行为管理， 根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券 第二条 本规范适用于本公司的控股股东、实际控制人、董事、高级管理人 员买卖公司股份的行为和信息披露管理等。 第三条 本规范所称控股股东是指直接持有本公司股本总额 50%以上的股东； 或者持有股份的比例虽然不足 50%，但依其持有的股份所享有的表决权已足以对 股东大会的决议产生重大影响的股东。 法》（以下简称"《证券法》"）、中国证监会《上市公司股东、董监高减持股份的 若干规定》 、《深圳证券交易所创业板股票上市规则》（以下简称"《创业板股票上 市规则》"）、《深圳证券交易所上市公司自律监管指引第 10 号—股份变动管理》 等法律、行政法规、部门规章、规范性文件以及《烟台正海生物科技股份有限公 司章程》 （以下简称"《公司章程》"）的有关规定，并结合本公司实际情 ...

烟台正海生物科技股份有限公司 独立董事工作制度 烟台正海生物科技股份有限公司 第一章 总则 第一条 为了规范独立董事的行为，明确本公司与独立董事的权责关系，依据 《中华人民共和国公司法》（以下简称《公司法》）、 《中华人民共和国证券法》、《上 市公司独立董事管理办法》（以下简称"《管理办法》"）等相关法律法规、规范性 文件及《烟台正海生物科技股份有限公司章程》（以下简称"《公司章程》"），制订 本制度。 第二条 独立董事是指不在公司担任除独立董事外的任何其他职务，并与公司 及公司主要股东、实际控制人不存在直接或者间接利害关系或其他可能影响妨碍 其进行独立客观判断的关系的董事。 第三条 独立董事独立履行职责,不受公司主要股东、实际控制人或者其他与 公司存在利害关系的单位或个人的影响。 第四条 独立董事对公司及全体股东负有忠实与勤勉义务，应当按照法律、行 政法规、中国证券监督管理委员会（以下简称"中国证监会"）规定、证券交易所 业务规则和《公司章程》的规定，认真履行职责，在董事会中发挥参与决策、监 督制衡、专业咨询作用，维护公司整体利益，保护中小股东合法权益。 第五条 公司董事会包括 3 名独立董事，其中至少包括 ...

烟台正海生物科技股份有限公司 第一章 总则 第一条 为维护烟台正海生物科技股份有限公司（以下简称"公司"）股东及 债权人的合法权益，规范公司股东会的组织和行为，根据《中华人民共和国公司 法》（以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）、 《上市公司股东会规则》、《上市公司章程指引》等法律、法规、规范性文件及《烟 台正海生物科技股份有限公司章程》（以下简称《公司章程》），制订本议事规则 （以下简称"本规则"）。 第二章 一般规定 第二条 股东会是公司的权力机构，依法行使下列职权： （六）对公司合并、分立、解散、清算或者变更公司形式作出决议； （十六）对公司因减少公司注册资本、与持有本公司股票的其他公司合并情 形而发生收购本公司股份的事项； （十七）公司年度股东会可以授权董事会决定向特定对象发行融资总额不超 过人民币 3 亿元且不超过最近一年末净资产 20%的股票，该授权在下一年度股东 会召开日失效； （一）单笔担保额超过公司最近一期经审计净资产 10%的担保； （二）公司及其控股子公司的提供担保总额，超过公司最近一期经审计净资 产 50%以后提供的任何担保； （三）为资产负债率超过 7 ...

烟台正海生物科技股份有限公司董事会 薪酬与考核委员会工作细则 第一章 总 则 第二条 薪酬与考核委员会为董事会下设的专门委员会，主要负责制定公司董事及高 级管理人员的考核标准并进行考核；负责制定、审查公司董事及高级管理人员的薪酬政 策与方案，对董事会负责。 第三条 本工作细则所称董事是指在本公司支取薪酬的董事，高级管理人员是指董事 会聘任的总经理、副总经理、董事会秘书、财务负责人以及董事会确定的其他高级管理 人员。 第二章 人员组成 第四条 薪酬与考核委员会成员由 3 名董事组成，其中独立董事 2 名。 第五条 薪酬与考核委员会委员（以下简称"委员"）由董事长、1/2 以上独立董事 或者全体董事的 1/3 以上提名，并由董事会选举产生。 第六条 薪酬与考核委员会设主任委员（召集人）1 名，由独立董事担任，负责主持 委员会工作。委员会主任委员由董事会指定。 当委员会主任委员不能或无法履行职责时，由其指定一名其他委员代行其职权；委 员会主任委员既不履行职责，也不指定其他委员代行其职责时，任何一名委员均可将有 关情况向公司董事会报告，由董事会指定一名委员履行薪酬与考核委员会主任委员职责。 第一条 为进一步建立健全烟 ...